• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial Officer

    2/15/23 8:00:00 AM ET
    $AGRX
    $PG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $AGRX alert in real time by email

    Appointment of Ernie De Paolantonio to Chief Financial Officer Further Strengthens Leadership Team

    GRAND RAPIDS, Mich., Feb. 15, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer. This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.

    Appointment of Ernie De Paloantonio to Chief Financial Officer Further Strengthens CPSI's Leadership Team

    Ernie brings over 30 years of financial and business experience in the pharmaceutical industry including both private and public commercial and manufacturing companies. Most recently, he was Chief Financial Officer of Journey Medical Corporation, a commercial stage dermatology company. Prior to that, he held several leadership positions throughout his career including Chief Financial Officer at Teligent, Inc., a specialty generic pharmaceutical company, Fortovia Therapeutics Inc., a privately held healthcare company, Chief Financial Officer, Secretary and Treasurer of BioDelivery Sciences International, Inc., a public specialty pharmaceutical company and Chief Financial Officer of CorePharma LLC, a privately held specialty generic company.

    As CFO, Ernie will have responsibility for both finance and information technology.

    "I am pleased to be able to work with Ernie again as we look to grow this promising specialty development and manufacturing business. Ernie will bring his over thirty years of financial experience across a spectrum of pharmaceutical companies to help drive the growth of Corium Pharma Solutions. He will play an instrumental role working closely with myself, members of the leadership team, and our investors on our long-term growth strategy and its execution," said Mark Sirgo, CEO of CPSI, in making the announcement.

    Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Solutions has maintained longstanding partnerships with multinational Fortune 500 companies and pharmaceutical businesses alike. CPSI currently manufactures a variety of over the counter and prescription products, including Proctor & Gamble Co's (NYSE:PG) entire Crest Whitestrips franchise, Agile Therapeutics, Inc.'s (NASDAQ:AGRX) Twirla®, and Corium, LLC's ("Corium") ADLARITY®, a once-weekly, transdermal donepezil patch.

    About Corium Pharma Solutions

    Headquartered in Grand Rapids, Michigan, Corium Pharma Solutions is a leading, full-service contract development and manufacturing organization specializing in novel drug and consumer product delivery technologies. With a track record spanning nearly 30 years, the company offers end-to-end solutions to its partners, from formulation and product development work, through commercial-scale manufacturing and packaging. The company's success is enabled by its state-of-the-art facilities, highly tenured operational leadership, and proprietary drug delivery technologies, CORPLEX™ and MICROCOR®. Corium Pharma Solutions is jointly owned by B-FLEXION and Webster Equity Partners. Prior to the CPSI transaction with Webster Equity Partners in October 2022, Gurnet Point Capital, an affiliate of B-Flexion, led the original investment in Corium Pharma Solutions through a take-private transaction in October 2018.

    About Gurnet Point Capital & B-FLEXION

    Gurnet Point Capital, an affiliate of B-FLEXION, is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point's team of highly experienced industry executives works closely with its portfolio companies, with an active approach driving operational transformation and outsized returns.

    www.gurnetpointcapital.com/

    B-FLEXION is a private, entrepreneurial investment firm, partnering with sophisticated capital to meet the shared goal of delivering exceptional value over the generations, while also contributing positively to society. The company oversees growth-oriented operating businesses and asset managers, always with an 'active owner' philosophy. B-FLEXION invests across a wide range of industries, including healthcare. Gurnet Point Capital, an affiliate of B-FLEXION, leads B-FLEXION's de-risked life sciences investment strategy.

    https://www.bflexion.com/

    About Webster Equity Partners

    Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for our investors, portfolio companies and the communities that we serve. Our mission is to deliver superior returns to our partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients. https://websterequitypartners.com/

    Contact

    Gartman PR

    (202) 413-4226

    Cision View original content:https://www.prnewswire.com/news-releases/corium-pharma-solutions-names-ernie-de-paolantonio-as-chief-financial-officer-301746886.html

    SOURCE Corium Pharma Solutions Inc.

    Get the next $AGRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRX
    $PG

    CompanyDatePrice TargetRatingAnalyst
    Procter & Gamble Company
    $PG
    1/7/2026$150.00Neutral
    Piper Sandler
    Procter & Gamble Company
    $PG
    12/17/2025$179.00Hold → Buy
    Jefferies
    Procter & Gamble Company
    $PG
    12/8/2025$153.00 → $151.00Equal Weight
    Barclays
    Procter & Gamble Company
    $PG
    12/8/2025$176.00 → $171.00Buy
    Deutsche Bank
    Procter & Gamble Company
    $PG
    7/25/2025$170.00Overweight → Neutral
    Analyst
    Procter & Gamble Company
    $PG
    7/14/2025$170.00Outperform → In-line
    Evercore ISI
    Procter & Gamble Company
    $PG
    5/1/2025$161.00Buy → Neutral
    Redburn Atlantic
    Procter & Gamble Company
    $PG
    4/25/2025$177.00Sector Perform → Outperform
    RBC Capital Mkts
    More analyst ratings

    $AGRX
    $PG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Portman Robert Jones was granted 54 shares, increasing direct ownership by 1% to 4,984 units (SEC Form 4)

    4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

    12/10/25 4:20:27 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Director Mcevoy Ashley was granted 215 shares, increasing direct ownership by 4% to 5,563 units (SEC Form 4)

    4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

    12/10/25 4:19:10 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Director Mccarthy Christine M was granted 269 shares, increasing direct ownership by 2% to 16,809 units (SEC Form 4)

    4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

    12/10/25 4:15:43 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    P&G Recommends Stockholders Reject Mini-Tender Offer by Potemkin Limited

    The Procter & Gamble Company (NYSE:PG) today announced that it has been notified of an unsolicited "mini-tender" offer by Potemkin Limited (Potemkin) to purchase up to 50,000 shares (or a greater amount as outlined in the offer documentation) of the Company's common stock at a price of $100.00 per share. The $100.00 per share offer price represents an approximately 31 percent discount to the closing price of $145.52 on December 18, 2025, the last trading day prior to the date of the offer. P&G shareholders who tender their shares in this offer will receive a below-market price. P&G recommends shareholders do not tender their shares in response to this unsolicited mini-tender offer because

    1/14/26 12:12:00 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    P&G Declares Quarterly Dividend, January 2026

    The Board of Directors of The Procter & Gamble Company (NYSE:PG) declared a quarterly dividend of $1.0568 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after February 17, 2026 to Common Stock shareowners of record at the close of business on January 23, 2026, and to Series A and Series B ESOP Convertible Class A Preferred Stock shareowners of record at the start of business on January 23, 2026. P&G has been paying a dividend for 135 consecutive years since its incorporation in 1890 and has increased its dividend for 69 consecutive years. This reinforces our commitment to return cash to shareowners, man

    1/13/26 4:15:00 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Bounty Returns as the Ultimate Wingman - Tackling Gameday Messes from Playoffs to Super Bowl LX

    The Quicker Picker Upper is back with NFL Star Rob Gronkowski and brings in rookie for his Wingman, sportscaster Charissa Thompson, to give fans the winning play against gameday's messiest food: wings + Bounty Back for its fourth year, the Bounty is Your Wingman campaign is built on the simple, saucy truth: you can't have football without wings, and you can't have wings without Bounty. As NFL fans across the country gear up for the most-watched games of the year, Bounty is once again showing up where it belongs, at the center of wing-filled watch parties, handling every spill, drip, and sticky-finger so fans can focus on the fun. This press release features multimedia. View the full rele

    1/8/26 9:00:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    SEC Filings

    View All

    Procter & Gamble Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PROCTER & GAMBLE Co (0000080424) (Filer)

    1/13/26 4:27:59 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Procter & Gamble Company filed SEC Form 8-K: Leadership Update

    8-K - PROCTER & GAMBLE Co (0000080424) (Filer)

    12/15/25 9:15:22 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 11-K filed by Procter & Gamble Company

    11-K - PROCTER & GAMBLE Co (0000080424) (Filer)

    12/5/25 9:26:25 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on Procter & Gamble with a new price target

    Piper Sandler resumed coverage of Procter & Gamble with a rating of Neutral and set a new price target of $150.00

    1/7/26 9:13:33 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Procter & Gamble upgraded by Jefferies with a new price target

    Jefferies upgraded Procter & Gamble from Hold to Buy and set a new price target of $179.00

    12/17/25 8:45:57 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Barclays reiterated coverage on Procter & Gamble with a new price target

    Barclays reiterated coverage of Procter & Gamble with a rating of Equal Weight and set a new price target of $151.00 from $153.00 previously

    12/8/25 10:19:41 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    Financials

    Live finance-specific insights

    View All

    P&G Declares Quarterly Dividend, January 2026

    The Board of Directors of The Procter & Gamble Company (NYSE:PG) declared a quarterly dividend of $1.0568 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after February 17, 2026 to Common Stock shareowners of record at the close of business on January 23, 2026, and to Series A and Series B ESOP Convertible Class A Preferred Stock shareowners of record at the start of business on January 23, 2026. P&G has been paying a dividend for 135 consecutive years since its incorporation in 1890 and has increased its dividend for 69 consecutive years. This reinforces our commitment to return cash to shareowners, man

    1/13/26 4:15:00 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    P&G Announces Fiscal Year 2026 First Quarter Results

    Net Sales +3%; Organic Sales +2% Diluted EPS $1.95, +21%; Core EPS $1.99, +3% MAINTAINS FISCAL YEAR SALES, EPS GROWTH AND CASH RETURN GUIDANCE The Procter & Gamble Company (NYSE:PG) reported first quarter fiscal year 2026 net sales of $22.4 billion, an increase of three percent versus the prior year. Organic sales, which excludes the impacts of foreign exchange and acquisitions and divestitures, increased two percent versus the prior year. Diluted net earnings per share were $1.95, an increase of 21% versus the prior year primarily due to higher non-core restructuring charges in the prior year. Core earnings per share were $1.99, an increase of three percent versus the prior year. O

    10/24/25 7:00:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    P&G Announces Fourth Quarter and Fiscal Year 2025 Results

    Q4 '25: Net Sales +2%; Organic Sales +2%; Diluted EPS +17%; Core EPS +6% FY '25: Net Sales 0%; Organic Sales +2%; Diluted EPS +8%; Core EPS +4% The Procter & Gamble Company (NYSE:PG) reported fourth quarter and fiscal year 2025 results. "We grew sales and profit in fiscal 2025 and returned high levels of cash to shareowners in a dynamic, difficult and volatile environment," said Jon Moeller, Chairman of the Board, President and Chief Executive Officer. "We've put in place strong plans to continue to deliver for all stakeholders in the current environment. In fiscal 2026, we expect to deliver another year of organic sales growth, Core EPS growth and strong adjusted free cash flow produ

    7/29/25 7:00:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    Leadership Updates

    Live Leadership Updates

    View All

    Downy and USA Hockey Announce Partnership By Sending One Lucky Fan To The Olympic and Paralympic Winter Games Milano Cortina 2026

    Downy Rinse Out Odor Launches Sweepstakes Offering Two Tickets to Watch The U.S. Men's Ice Hockey Team Play On February 14. Downy, the laundry care brand from Procter & Gamble, is celebrating its new partnership with USA Hockey by launching a sweepstakes offering a once-in-a-lifetime trip: two tickets to the Winter Olympics to cheer on the U.S. Men's Ice Hockey Team on February 14, 2026. Fans can enter* for their chance to win from now until January 2, 2026, at DownyRinseSweepstakes.com/OlympicWinterGames. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215669968/en/ Through this partnership, Downy Rinse is bringing its odor-f

    12/15/25 8:00:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Herbal Essences Unveils "Scent Traps" Campaign Featuring Amaya Espinal: Turning Scent Into the Ultimate Dating Hack

    Get ready to turn heads and spark memories! Herbal Essences is excited to introduce its latest campaign, "Scent Traps," starring the charismatic Amaya Espinal from Love Island. Inspired by that feeling of wanting to stay on your crush's mind, this innovative campaign highlights the enchanting power of scent—showing that what lingers in your hair can linger in someone's heart. With the iconic fragrance of Herbal Essences, you can use the power of scent to stir up memories of you even when you're not around. Herbal Essences is more than just an unforgettable scent…it's the ultimate dating hack. This press release features multimedia. View the full release here: https://www.businesswire.com/n

    10/15/25 9:40:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    P&G Declares Quarterly Dividend At October 2025 Board of Directors Meeting

    P&G Shareholders Also Elect All 14 P&G Director Nominees at 2025 Annual Meeting The Procter & Gamble Company (NYSE:PG) announced at today's Annual Meeting of Shareholders that the P&G Board of Directors declared a quarterly dividend of $1.0568 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after November 17, 2025 to Common Stock shareholders of record at the close of business on October 24, 2025, and to Series A and Series B ESOP Convertible Class A Preferred Stock shareholders of record at the start of business on October 24, 2025. P&G has been paying a dividend for 135 consecutive years since its in

    10/14/25 10:34:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Agile Therapeutics Inc.

    SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

    7/22/24 4:50:46 PM ET
    $AGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Agile Therapeutics Inc.

    SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

    7/9/24 2:20:54 PM ET
    $AGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Agile Therapeutics Inc.

    SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

    7/2/24 3:44:23 PM ET
    $AGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care